Using Radiomics to Predict Neoadjuvant Chemotherapy Efficacy

Study Overview
=================
Brief Summary
-----------------
Neoadjuvant chemotherapy (NC) is an important treatment for advanced gastric cancer (AGC). However, tools that effectively predict the efficacy of NC before treatment are lacking. Computed tomography images before and after NC were used to construct a deep learning-based radiomics signature to predict the efficacy of NC, prognoses and postoperative adjuvant chemotherapy benefit.

Detailed Description
-----------------
Background: Neoadjuvant chemotherapy (NC) is an important treatment for advanced gastric cancer (AGC). However, tools that effectively predict the efficacy of NC before treatment are lacking. Methods: Computed tomography images before and after NC were used to construct a deep learning-based radiomics signature to predict the efficacy of NC, prognoses and postoperative adjuvant chemotherapy benefit. Tumor regression grade (TRG) =0 or 1 was defined as a good response to neoadjuvant chemotherapy (GRNC), and TRG=2 or 3 was defined as a poor response to neoadjuvant chemotherapy (PRNC). 193 patients with AGC from January 2010 to December 2018 in two different China university hospitals were included in this study. The before neoadjuvant chemotherapy imaging scoring system (BNCISS), imaging change scoring system before and after neoadjuvant chemotherapy (ICSS), which were constructed based on computed tomography images before after treatment.

Official Title
-----------------
Using Radiomics to Predict Neoadjuvant Chemotherapy Efficacy and Postoperative Adjuvant Chemotherapy Benefit in Advanced Gastric Cancer: a Two-center Study

Conditions
-----------------
Gastric Cancer

Intervention / Treatment
-----------------
* Other: response to neoadjuvant chemotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Prospective collection and a retrospective analysis of patients seen from January 2010 to December 2018 at Fujian Medical University Union Hospital (FMUUH) and the First Hospital of Lanzhou University (FHLU) who were diagnosed with gastric adenocarcinoma and underwent radical resection Exclusion Criteria: Patients with concurrent malignant disease, distant metastases, palliative resection, or gastric stump cancer were excluded.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| good response to neoadjuvant chemotherapy (GRNC)<br>Tumor regression grade (TRG) =0 or 1 was defined as a good response to neoadjuvant chemotherapy (GRNC) | Other: response to neoadjuvant chemotherapy<br>* Tumor regression grade (TRG) =0 or 1 was defined as a good response to neoadjuvant chemotherapy (GRNC), and TRG=2 or 3 was defined as a poor response to neoadjuvant chemotherapy (PRNC).<br>|
| poor response to neoadjuvant chemotherapy (PRNC)<br>TRG=2 or 3 was defined as a poor response to neoadjuvant chemotherapy (PRNC). | Other: response to neoadjuvant chemotherapy<br>* Tumor regression grade (TRG) =0 or 1 was defined as a good response to neoadjuvant chemotherapy (GRNC), and TRG=2 or 3 was defined as a poor response to neoadjuvant chemotherapy (PRNC).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUC for ICSS | The predictive performance of imaging change scoring system before and after neoadjuvant chemotherapy (ICSS) | 2022-01-01 to 2022-07-31 | 
| AUC for BNCISS | The predictive performance of before neoadjuvant chemotherapy imaging scoring system (BNCISS) | 2022-01-01 to 2022-07-31 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall survival | 3 year overall survival | 2010-01-01 to 2022-07-31 | 
| disease free survival | 3 year disease free survival | 2010-01-01 to 2022-07-31 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
tumor regression grade, radiomics, neoadjuvant chemotherapy, advanced gastric cancer, chemotherapy benefit